Cargando…
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
BACKGROUND: Outcome in multiple myeloma (MM) has improved substantially over recent years as a result of the availability of multiple novel agents with acceptable safety profile. STUDY DESIGN: Prospective observational study at a tertiary care institute. METHODS: Twenty-five newly diagnosed patients...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865101/ https://www.ncbi.nlm.nih.gov/pubmed/29600238 http://dx.doi.org/10.4103/sajc.sajc_59_17 |
_version_ | 1783308618400006144 |
---|---|
author | Hassan Zafar, Mir Sadaqat Khan, Afaq Ahmed Aggarwal, Shyam Bhargava, Manorama |
author_facet | Hassan Zafar, Mir Sadaqat Khan, Afaq Ahmed Aggarwal, Shyam Bhargava, Manorama |
author_sort | Hassan Zafar, Mir Sadaqat |
collection | PubMed |
description | BACKGROUND: Outcome in multiple myeloma (MM) has improved substantially over recent years as a result of the availability of multiple novel agents with acceptable safety profile. STUDY DESIGN: Prospective observational study at a tertiary care institute. METHODS: Twenty-five newly diagnosed patients of MM were treated with bortezomib and dexamethasone induction with monitoring for response and safety, followed by peripheral blood autologous stem cell transplant (PBASCT) in eligible patients or maintenance. RESULTS: Out of 25 patients, 32% attained complete response (CR), 56% very good partial response (VGPR), 4% PR, and 8% showed no response. The overall response rate was 92%. In our study, 56% of patients showed hematological side effects, out of which thrombocytopenia was seen in 32%, anemia in 16%, and leukopenia in 8%. Six patients developed bortezomib-induced peripheral neuropathy, out of which four had grade 1 (66.66%), one had grade 2 (16.66%), and 1 (16.66%) had grade 3 toxicity. Sixteen patients were eligible for PBASCT, out of which eight patients received this therapy while as remaining eight patients opted for two more cycles of induction therapy followed by maintenance. After completing 18 months of maintenance, all the eight patients who underwent PBASCT were in CR. Out of the 15 patients who did not receive PBASCT five attained CR, eight VGPR while as two patients relapsed. CONCLUSION: Bortezomib plus dexamethasone is highly effective and well-tolerated regimen for frontline treatment of MM with a higher quality of response in an advanced stage and renal failure patients. |
format | Online Article Text |
id | pubmed-5865101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-58651012018-03-29 Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma Hassan Zafar, Mir Sadaqat Khan, Afaq Ahmed Aggarwal, Shyam Bhargava, Manorama South Asian J Cancer ORIGINAL ARTICLE: Leukemia, Lymphoma & Plasma Cell Disorder BACKGROUND: Outcome in multiple myeloma (MM) has improved substantially over recent years as a result of the availability of multiple novel agents with acceptable safety profile. STUDY DESIGN: Prospective observational study at a tertiary care institute. METHODS: Twenty-five newly diagnosed patients of MM were treated with bortezomib and dexamethasone induction with monitoring for response and safety, followed by peripheral blood autologous stem cell transplant (PBASCT) in eligible patients or maintenance. RESULTS: Out of 25 patients, 32% attained complete response (CR), 56% very good partial response (VGPR), 4% PR, and 8% showed no response. The overall response rate was 92%. In our study, 56% of patients showed hematological side effects, out of which thrombocytopenia was seen in 32%, anemia in 16%, and leukopenia in 8%. Six patients developed bortezomib-induced peripheral neuropathy, out of which four had grade 1 (66.66%), one had grade 2 (16.66%), and 1 (16.66%) had grade 3 toxicity. Sixteen patients were eligible for PBASCT, out of which eight patients received this therapy while as remaining eight patients opted for two more cycles of induction therapy followed by maintenance. After completing 18 months of maintenance, all the eight patients who underwent PBASCT were in CR. Out of the 15 patients who did not receive PBASCT five attained CR, eight VGPR while as two patients relapsed. CONCLUSION: Bortezomib plus dexamethasone is highly effective and well-tolerated regimen for frontline treatment of MM with a higher quality of response in an advanced stage and renal failure patients. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC5865101/ /pubmed/29600238 http://dx.doi.org/10.4103/sajc.sajc_59_17 Text en Copyright: © 2018 The South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | ORIGINAL ARTICLE: Leukemia, Lymphoma & Plasma Cell Disorder Hassan Zafar, Mir Sadaqat Khan, Afaq Ahmed Aggarwal, Shyam Bhargava, Manorama Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma |
title | Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma |
title_full | Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma |
title_fullStr | Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma |
title_full_unstemmed | Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma |
title_short | Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma |
title_sort | efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma |
topic | ORIGINAL ARTICLE: Leukemia, Lymphoma & Plasma Cell Disorder |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865101/ https://www.ncbi.nlm.nih.gov/pubmed/29600238 http://dx.doi.org/10.4103/sajc.sajc_59_17 |
work_keys_str_mv | AT hassanzafarmirsadaqat efficacyandtolerabilityofbortezomibanddexamethasoneinnewlydiagnosedmultiplemyeloma AT khanafaqahmed efficacyandtolerabilityofbortezomibanddexamethasoneinnewlydiagnosedmultiplemyeloma AT aggarwalshyam efficacyandtolerabilityofbortezomibanddexamethasoneinnewlydiagnosedmultiplemyeloma AT bhargavamanorama efficacyandtolerabilityofbortezomibanddexamethasoneinnewlydiagnosedmultiplemyeloma |